Ethics of human experimentation in early medical research: lessons for modern regulation.

Early drug discovery advanced on subjects who were rarely asked. A 1926 report from Duesseldorf hailed Plasmochin, the first synthetic antimalarial claimed to surpass quinine, after trials on patients deliberately infected with malaria, including inmates of a mental asylum [1]. That episode captures both the scientific promise and the ethical deficit of early research.

Ethical failings of early experimentation

• Absence of voluntary consent: subjects were deliberately infected rather than informed and asked; consent was neither sought nor recorded [1].
• Use of vulnerable groups: institutionalised mentally ill persons, prisoners and colonial populations were chosen for availability, not for scientific fit — a group modern codes single out for extra protection [3].
• Weak risk–benefit assessment: Plasmochin (pamaquine) was later abandoned as too toxic, its safer successor primaquine appearing only in 1952 — harm that pre-trial toxicity review might have limited.
• Overstated claims without oversight: "permanent cure is believed to have been effected" was asserted with no independent committee to test it [1].
• No compensation or follow-up for injury caused by research participation.

Lessons carried into modern regulation

• Consent as a non-negotiable: the Nuremberg Code, 1947 opens with "the voluntary consent of the human subject is absolutely essential" [2]; the WMA Declaration of Helsinki, revised in 2024, extends this to transparency and equity for vulnerable participants [3].
• Institutional gatekeeping: India's ICMR National Ethical Guidelines, 2017 mandate independent ethics committee review of all biomedical and health research [4].
• Statutory force: the New Drugs and Clinical Trials Rules, 2019 require ethics committee registration, audio-visual informed consent and compensation for trial-related injury [5].
• Safety screening before therapy: WHO's advice to test for G6PD deficiency before prescribing primaquine shows the same precautionary logic now built into clinical practice [6].

A century on, the science of that era survives while its methods do not. The task ahead is to keep ethics committees genuinely independent and consent genuinely understood, so that innovation in genomics, AI-enabled trials and vaccines advances with the dignity guaranteed under Article 21 — proof that rigorous ethics accelerates, rather than obstructs, good medicine.